Loading [Contrib]/a11y/accessibility-menu.js
JHEOR
Menu
Articles
Author Correction
Autoimmune Diseases
Cardiovascular Conditions
Commentary
Correspondence
Dermatological Diseases
Endocrine Diseases
Gastrointestinal Conditions
General Indications
Hematology
Hereditary Genetic Disorders
Infectious Diseases
Methodology and Healthcare Policy
Nephrologic/Hepatologic Conditions
Neurological Diseases
Oncology
Ophthalmology
Other Conditions
Perspective
Psychological Conditions
Respiratory Diseases
Trauma Induced Conditions
Urological/Gynecological Diseases
All
For Authors
Editorial Board
About
Issues
Blog
Journal Policies
For Reviewers
search
Sorry, something went wrong. Please try your search again.
×
Articles
Blog posts
RSS Feed
Enter the URL below into your favorite RSS reader.
https://jheor.org/feed
×
Ophthalmology
Vol. 2, Issue 2, 2015
January 20, 2015 EDT
Comparing Prednisone and Methotrexate to Off-label Biologic Infliximab for Management of Ocular Uveitis: A Cost-minimization Analysis
William V. Padula
,
Miguel Cordero-Coma
,
Taygan Yilmaz
,
William V. Padula
,
Michéal J. Gallagher
,
Jonathan D. Campbell
,
autoimmune disease
biologic
uveitis
ophthalmology
cost-minimization analysis
Copyright Logo
ccby-4.0
•
https://doi.org/10.36469/9895
JHEOR
1.
Padula WV, Cordero-Coma M, Yilmaz T, Padula WV, Gallagher MJ, Campbell JD. Comparing Prednisone and Methotrexate to Off-label Biologic Infliximab for Management of Ocular Uveitis: A Cost-minimization Analysis.
JHEOR
. 2015;2(2):131-146.
doi:10.36469/9895
Save article as...
▾
PDF
XML
Citation (BibTeX)
View more stats